
Combination Multiplication: A Compounding Return for Oncology
Combinations are not new. What is new is the velocity. The number of regimens pairing established immuno-oncology (IO) agents with novel molecules and mechanisms has grown significantly year over year, and the data supporting those pairings is maturing in ways that carry real implications for patients, drugmakers, and the broader life sciences investment thesis.
Read More











